The US Preventive Services Task Force recommends that kids 6 years and older with a high body mass index receive intensive behavioral interventions; Amazon’s pharmacy unit is expanding eligibility for RxPass to patients enrolled in Medicare insurance plans; Sen Bernie Sanders (I, Vermont) is trying to lower the prices of popular antiobesity drugs.
The US Preventive Services Task Force recommends that kids aged 6 years and older with a high body mass index receive intensive behavioral interventions, according to NPR. This replaces its prior recommendations from 2017 that simply advise primary care providers to screen children for obesity. Task Force Chair Wanda Nicholson, MD, MPH, MBA, noted that evidence shows that having children with obesity undergo behavioral counseling interventions for at least 26 hours can help them achieve a healthy weight and improve their quality of life. Behavioral interventions involve education on healthy eating habits, counseling on weight-related behavioral changes, and supervised exercise sessions. Conversely, the recommendations do not include prescribing antiobesity drugs as there is not enough research yet to assess their value in this age group.
Amazon’s pharmacy unit announced Tuesday that it is expanding eligibility for RxPass, its monthly subscription service that covers a range of generic drugs, to patients enrolled in Medicare insurance plans, according to Reuters. With this expansion, Amazon noted that over 50 million more people will be eligible for RxPass, which was launched for $5 a month in January 2023 for US Amazon Prime members. This subscription gives patients access to 60 eligible generic medications, 24/7 access to a pharmacist, and free doorstep treatment deliveries for Prime members. Through RxPass, Amazon Pharmacy offers up to 80% off generic drug costs and up to 40% off brand-name medicines for subscribers with or without insurance. Amazon explained that RxPass could help lower out-of-pocket costs for older adults and reduce Medicare spending by about $2 billion annually.
Sen Bernie Sanders (I, Vermont) is trying to lower the prices of popular antiobesity drugs as he did for inhaler and insulin costs, according to Axios. Sanders, chair of the Senate Health Committee, is acting because the rising demand for drugs like semaglutide (Novo Nordisk’s Wegovy and Ozempic) could strain Medicare and patients’ wallets as drug manufacturers are unwilling to change list prices; Ozempic costs about $600 per month in the US compared with $59 in Germany. Consequently, Sanders announced that he will question Novo Nordisk CEO Lars Fruergaard Jørgensen later this summer during a Senate Health Committee hearing. He acknowledged that getting the company to agree to lower drug prices will not be easy, but being in the spotlight may make a difference; bringing attention to the issue may cause them to feel pressured to lower US drug prices.
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Health Equity & Access Weekly Roundup: April 14, 2025
April 14th 2025From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
Read More